In addition, we divided patients with MDS into four groups: lower-risk MDS patients with lower caspase-3 levels (n = 32), lower-risk MDS patients with higher caspase-3 levels (n = 13), higher-risk MDS patients with lower caspase-3 levels (n = 28), and higher-risk MDS patients with higher caspase-3 levels (n = 2). Here, CASP3 is linked to myelodysplastic syndrome.